Johns Hopkins ABX Guide
Kanamycin
Kanamycin is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Short-term treatment of infections caused by E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species.
- Note: other aminoglycosides including gentamicin, tobramycin, and/or amikacin are preferred in this setting.
- Staphylococcal infections (not drug of choice)
- Hepatic encephalopathy (oral formulation, no longer available in the U.S.)
- Bowel decontamination (oral formulation, no longer available in the U.S.)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of multi-drug resistant Mycobacterium tuberculosis (second line)
- Non-tubercular mycobacterial (NTM) infections
- Gonorrhea
- Urinary tract infections
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Short-term treatment of infections caused by E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species.
- Note: other aminoglycosides including gentamicin, tobramycin, and/or amikacin are preferred in this setting.
- Staphylococcal infections (not drug of choice)
- Hepatic encephalopathy (oral formulation, no longer available in the U.S.)
- Bowel decontamination (oral formulation, no longer available in the U.S.)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of multi-drug resistant Mycobacterium tuberculosis (second line)
- Non-tubercular mycobacterial (NTM) infections
- Gonorrhea
- Urinary tract infections
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 30, 2018
Citation
Dzintars, Kathryn, and Paul A Pham. "Kanamycin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540299/all/Kanamycin.
Dzintars K, Pham PA. Kanamycin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540299/all/Kanamycin. Accessed October 1, 2022.
Dzintars, K., & Pham, P. A. (2018). Kanamycin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540299/all/Kanamycin
Dzintars K, Pham PA. Kanamycin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2022 October 01]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540299/all/Kanamycin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Kanamycin
ID - 540299
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2018/09/30/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540299/all/Kanamycin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
